


GSK delivers strong 2024 performance with further improvement to long-term growth outlook

“GSK delivered another year of excellent performance in 2024, with strong sales and core profit growth driven by accelerating momentum of our specialty medicines portfolio. This, together with outstanding phase III pipeline progress, means we expect another year of profitable growth in 2025, and have further improved our long-term outlook, with sales of more than £40 billion now expected by 2031. In particular, we are increasing and prioritising R&D investment to promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV. Our outperformance and stronger balance sheet support these investments and others planned in R&D, as well as the opportunity to enhance shareholder returns through our progressive dividend and the share buyback programme which we have set out today.”

Emma Walmsley
Chief Executive Officer, GSK



Specialty Medicines

£11.8bn +19%

Respiratory, Immunology and Inflammation
+13% Oncology +98% HIV +13%

Vaccines

£9.1bn -4%, -3%

including and excluding COVID-19 solutions

General Medicines

£10.4bn +6%

Core operating profit

£9.1bn
+11%, +13%

including and excluding COVID-19 solutions

Total EPS

63.2p
-40%

Core EPS

159.3p
+10%, +12%

including and excluding COVID-19 solutions

Dividend Q4

16p

FY

61p

13
positive phase III readouts in 2024

5
major new product approvals expected in 2025

Specialty Medicines and Vaccines

71
in clinical development

19
in phase III/ registration

2025 guidance

Turnover growth
3-5%

Core operating profit growth
6-8%

2031 sales outlook

>£40 billion
increased from >£38 billion



Journalists/media see press release on www.gsk.com for full details on full-year and Q4 2024. Please read “Guidance and outlooks, assumptions and cautionary statements” on page 52 of the press release and the definitions and reconciliations for non-IFRS measures on pages 17-20 and 50-51 of the press release. Product group sales may not add to total sales due to rounding. References to growth are at constant exchange rates (CER) unless stated otherwise.

Ahead Together